DURECT Corporation Announces Sale of ALZET Product Line to Lafayette Instrument Co. for 17.5 Million
DRRX Stock | USD 0.77 0.02 2.53% |
Slightly above 56% of all Durect's investors are looking to take a long position. The analysis of overall sentiment of trading Durect stock suggests that some investors are interested at this time. Durect's investing sentiment can be driven by a variety of factors including economic data, Durect's earnings reports, geopolitical events, and overall market trends.
Durect |
DURECT Corporation , a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET line of osmotic pumps to Lafayette Instrument Co. , a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
Read at finance.yahoo.com
![]() |
Durect Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Durect can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Durect Fundamental Analysis
We analyze Durect's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Durect using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Durect based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Durect is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Durect Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Durect stock to make a market-neutral strategy. Peer analysis of Durect could also be used in its relative valuation, which is a method of valuing Durect by comparing valuation metrics with similar companies.
Peers
Durect Related Equities
LFCR | Lifecore Biomedical | 2.78 | ||||
NBIX | Neurocrine Biosciences | 1.04 | ||||
TKNO | Alpha Teknova | 0.00 | ||||
IRWD | Ironwood Pharmaceuticals | 0.00 | ||||
ORGO | Organogenesis Holdings | 0.00 | ||||
EVOK | Evoke Pharma | 0.00 | ||||
ALKS | Alkermes Plc | 0.54 | ||||
AQST | Aquestive Therapeutics | 1.07 | ||||
SNOA | Sonoma Pharmaceuticals | 1.26 | ||||
AVDL | Avadel Pharmaceuticals | 2.35 | ||||
COLL | Collegium Pharmaceutical | 2.54 | ||||
SHPH | Shuttle Pharmaceuticals | 3.33 | ||||
RDHL | Redhill Biopharma | 14.12 |
Additional Tools for Durect Stock Analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.